ESR1 and breast carcinoma: A large scale tissue microarray study involving about 4,000 patients documented that the expression of eIF4A and eIF4B can predict the clinical outcome in estrogen receptor-negative (ER-) breast cancer and was statistically independent from other known prognostic factors (58).